Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JENNIFER L HSIAO

Allopathic & Osteopathic Physicians Dermatology

NPI
1548559131
CMS profile
1307210
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$356,121.08

216 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JENNIFER L HSIAO

NPI 1548559131 · CMS profile ID 1307210

Allopathic & Osteopathic Physicians / Dermatology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548559131?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JENNIFER L HSIAO, NPI 1548559131, CMS profile ID 1307210. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548559131?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JENNIFER L HSIAO, NPI 1548559131, CMS profile ID 1307210. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548559131?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JENNIFER L HSIAO, NPI 1548559131, CMS profile ID 1307210, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1548559131?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

216 matching records · $356,121.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 216 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 216.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $2,425.0004/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224704703 CMS
UCB, Inc. $201.5004/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224704693 CMS
UCB, Inc. $326.9704/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224704697 CMS
LEO Pharma Inc. $40.1404/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252012079 CMS
UCB, Inc. $55.0004/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224704687 CMS
ABBVIE INC. $103.8004/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202072337 CMS
Regeneron Healthcare Solutions, Inc. $11,938.0004/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212945727 CMS
Regeneron Healthcare Solutions, Inc. $60.8204/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212945729 CMS
Regeneron Healthcare Solutions, Inc. $14.1404/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212945731 CMS
Regeneron Healthcare Solutions, Inc. $43.5504/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212945733 CMS
Regeneron Healthcare Solutions, Inc. $4,298.0004/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212945735 CMS
ABBVIE INC. $2,400.0004/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202072335 CMS
Galderma Laboratories, L.P. $3,600.0004/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234656156 CMS
Regeneron Healthcare Solutions, Inc. $417.8403/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212945721 CMS
Regeneron Healthcare Solutions, Inc. $274.0103/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212945723 CMS
Regeneron Healthcare Solutions, Inc. $364.8603/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212945725 CMS
LEO Pharma Inc. $39.0803/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252012077 CMS
Regeneron Healthcare Solutions, Inc. $264.4803/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212945719 CMS
UCB, Inc. $28.9703/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224704651 CMS
UCB, Inc. $29.5603/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224704655 CMS
UCB, Inc. $43.3303/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224704659 CMS
UCB, Inc. $45.3303/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224704663 CMS
UCB, Inc. $57.3803/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224704667 CMS
UCB, Inc. $1,800.0003/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224704671 CMS
UCB, Inc. $3,600.0003/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224704674 CMS
UCB, Inc. $3,880.0003/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224704678 CMS
UCB, Inc. $3,880.0003/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224704681 CMS
UCB, Inc. $7,200.0003/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224704684 CMS
Galderma Laboratories, L.P. $128.1503/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234656154 CMS
Regeneron Healthcare Solutions, Inc. $295.4803/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212945715 CMS
Regeneron Healthcare Solutions, Inc. $178.4903/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212945717 CMS
ABBVIE INC. $17.2303/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202072333 CMS
UCB, Inc. $12.8203/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224704646 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.5902/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223017674 CMS
UCB, Inc. $2.5202/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224704639 CMS
UCB, Inc. $10.1102/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224704643 CMS
Galderma Laboratories, L.P. $2,362.5002/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234656152 CMS
UCB, Inc. $2,425.0002/11/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224704635 CMS
Organon LLC $28.8102/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237732309 CMS
Incyte Corporation $37.8402/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226066574 CMS
GENZYME CORPORATION $138.0102/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233612471 CMS
Galderma Laboratories, L.P. $11.6102/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234656150 CMS
Novartis Pharmaceuticals Corporation $7.7302/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200346690 CMS
GENZYME CORPORATION $116.9402/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233612451 CMS
Regeneron Healthcare Solutions, Inc. $17.6101/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212945713 CMS
GENZYME CORPORATION $19,044.5001/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233612479 CMS
GENZYME CORPORATION $1,160.0001/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233612481 CMS
GENZYME CORPORATION $3,151.8301/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233612483 CMS
GENZYME CORPORATION $185.5201/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233612485 CMS
UCB, Inc. $1,800.0001/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224651727 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $446.05 6
PY2021 $28,387.37 18
PY2022 $52,013.30 44
PY2023 $52,312.27 66
PY2024 $256,726.42 239
PY2025 $356,121.08 216

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,040.67 2
PY2025 Principal investigator $189,566.02 216
PY2024 Principal investigator $181,178.50 205
PY2023 Recipient $1,559.23 2
PY2023 Principal investigator $28,550.93 44
PY2022 Recipient $12,561.00 5
PY2022 Principal investigator $35.06 1
PY2021 Recipient $2,490.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

218 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $750.00 12/10/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610222
Principal investigator 1 Incyte Corporation $2,785.25 12/08/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610234
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482229
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482291
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482315
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482319
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482325
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482331
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482338
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482345
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482360
Principal investigator 1 Incyte Corporation $686.45 11/24/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610154
Principal investigator 1 Incyte Corporation $1,721.00 11/24/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610170
Principal investigator 1 Incyte Corporation $1,721.00 11/24/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610173
Principal investigator 1 Incyte Corporation $1,721.00 11/24/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610177
Principal investigator 1 Incyte Corporation $1,609.00 11/24/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610247
Principal investigator 1 Incyte Corporation $3,000.00 11/20/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240608743
Principal investigator 1 Incyte Corporation $1,100.00 11/20/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240608747
Principal investigator 1 Incyte Corporation $1,500.00 11/20/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240608752
Principal investigator 1 Incyte Corporation $7,755.00 11/20/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240608756
Principal investigator 1 Incyte Corporation $4,050.00 11/20/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240608760
Principal investigator 1 Incyte Corporation $1,991.20 11/12/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610230
Principal investigator 1 Incyte Corporation $1,500.00 11/05/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610145
Principal investigator 1 Incyte Corporation $3,000.00 11/05/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610159
Principal investigator 1 Incyte Corporation $13,450.00 11/05/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240610209
Principal investigator 1 Incyte Corporation $125.95 11/03/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482232
Principal investigator 1 Incyte Corporation $270.80 11/03/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482351
Recipient Novartis Pharmaceuticals Corporation $3,391.29 10/31/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190292040
Principal investigator 1 Incyte Corporation $706.40 10/20/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610187
Principal investigator 1 Incyte Corporation $1,079.00 10/20/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610190
Principal investigator 1 Incyte Corporation $1,609.00 10/20/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610213
Principal investigator 1 Incyte Corporation $1,609.00 10/20/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610218
Principal investigator 1 Incyte Corporation $2,076.00 10/20/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610250
Principal investigator 1 Incyte Corporation $1,334.15 10/08/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610227
Principal investigator 1 Incyte Corporation $2,096.00 10/08/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610237
Principal investigator 1 Incyte Corporation $2,096.00 10/08/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610240
Principal investigator 1 Incyte Corporation $750.00 10/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610162
Principal investigator 1 Incyte Corporation $1,972.20 10/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610183
Principal investigator 1 Incyte Corporation $270.80 10/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482222
Principal investigator 1 Incyte Corporation $16.18 10/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482238
Principal investigator 1 Incyte Corporation $16.44 10/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482244
Principal investigator 1 Incyte Corporation $16.44 10/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482249
Principal investigator 1 Incyte Corporation $16.44 10/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482254
Principal investigator 1 Incyte Corporation $16.44 10/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482260
Principal investigator 1 Incyte Corporation $16.44 10/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482266
Principal investigator 1 Incyte Corporation $16.44 10/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482272
Principal investigator 1 Incyte Corporation $16.44 10/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482277
Principal investigator 1 Incyte Corporation $16.44 10/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482286
Principal investigator 1 Incyte Corporation $24.68 10/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482297
Principal investigator 1 Incyte Corporation $49.36 10/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482305
Principal investigator 1 Incyte Corporation $11.45 10/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482357
Principal investigator 1 Incyte Corporation $4.24 10/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482365
Principal investigator 1 Incyte Corporation $4.24 10/01/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482371
Principal investigator 1 Incyte Corporation $24.68 10/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610149
Principal investigator 1 Incyte Corporation $0.31 10/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610166
Principal investigator 1 Incyte Corporation $7.29 10/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610181
Principal investigator 1 Incyte Corporation $8.22 10/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610193
Principal investigator 1 Incyte Corporation $8.22 10/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610197
Principal investigator 1 Incyte Corporation $8.22 10/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610201
Principal investigator 1 Incyte Corporation $8.22 10/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610205
Principal investigator 1 Incyte Corporation $32.36 10/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610243
Principal investigator 1 Incyte Corporation $1,462.50 09/10/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610047
Principal investigator 1 Incyte Corporation $1,625.00 09/10/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610142
Principal investigator 1 Incyte Corporation $750.00 09/08/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610097
Principal investigator 1 Incyte Corporation $54.76 09/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610118
Principal investigator 1 Incyte Corporation $1,367.65 08/20/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610045
Principal investigator 1 Incyte Corporation $1,609.00 08/20/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610134
Principal investigator 1 Incyte Corporation $1,609.00 08/20/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610138
Principal investigator 1 Incyte Corporation $54.76 08/04/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610090
Principal investigator 1 Incyte Corporation $1,381.25 08/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610055
Principal investigator 1 Incyte Corporation $1,625.00 08/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610127
Principal investigator 1 Incyte Corporation $1,625.00 08/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610131
Principal investigator 1 Incyte Corporation $1,528.55 07/18/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610051
Principal investigator 1 Incyte Corporation $1,543.75 07/09/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610122
Principal investigator 1 Incyte Corporation $109.52 07/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610058
Principal investigator 1 Incyte Corporation $24.66 07/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610063
Principal investigator 1 Incyte Corporation $48.54 07/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610067
Principal investigator 1 Incyte Corporation $270.80 07/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610071
Principal investigator 1 Incyte Corporation $11.45 07/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610075
Principal investigator 1 Incyte Corporation $4.86 07/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610078
Principal investigator 1 Incyte Corporation $68.70 07/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610081
Principal investigator 1 Incyte Corporation $32.36 07/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610085
Principal investigator 1 Incyte Corporation $135.40 07/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610094
Principal investigator 1 Incyte Corporation $24.66 07/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610102
Principal investigator 1 Incyte Corporation $24.66 07/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610107
Principal investigator 1 Incyte Corporation $24.66 07/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610111
Principal investigator 1 Incyte Corporation $6.36 07/01/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610114
Principal investigator 1 Incyte Corporation $1,609.00 06/25/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609962
Principal investigator 1 Incyte Corporation $2,076.00 06/25/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609965
Principal investigator 1 Incyte Corporation $1,701.90 06/25/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609968
Principal investigator 1 Incyte Corporation $1,721.00 06/25/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609972
Principal investigator 1 Incyte Corporation $1,276.45 06/11/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609976
Principal investigator 1 Incyte Corporation $2,096.00 06/11/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609979
Principal investigator 1 Incyte Corporation $1,625.00 06/11/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609993
Principal investigator 1 Incyte Corporation $1,625.00 06/11/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609997
Principal investigator 1 Incyte Corporation $10.30 06/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609903
Principal investigator 1 Incyte Corporation $68.70 06/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609909
Principal investigator 1 Incyte Corporation $135.40 06/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609913
Principal investigator 1 Incyte Corporation $62.27 06/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609916
Principal investigator 1 Incyte Corporation $45.80 06/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610012
Principal investigator 1 Incyte Corporation $1,468.45 05/21/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609945
Principal investigator 1 Incyte Corporation $1,721.00 05/21/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609950
Principal investigator 1 Incyte Corporation $1,609.00 05/21/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609958
Principal investigator 1 Incyte Corporation $864.15 05/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609920
Principal investigator 1 Incyte Corporation $1,462.50 05/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609954
Principal investigator 1 Incyte Corporation $1,609.00 05/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609983
Principal investigator 1 Incyte Corporation $1,609.00 05/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609986
Principal investigator 1 Incyte Corporation $1,625.00 05/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610024
Principal investigator 1 Amgen Inc. $9,650.00 04/24/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) No dispute reported 06/30/2026 1246650828
Recipient Novartis Pharmaceuticals Corporation $7,649.38 04/21/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190292547
Principal investigator 1 Incyte Corporation $1,902.75 04/09/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609925
Principal investigator 1 Incyte Corporation $1,769.00 04/09/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609941
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482154
Principal investigator 1 Incyte Corporation $4.86 04/02/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482159
Principal investigator 1 Incyte Corporation $135.40 04/02/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482168
Principal investigator 1 Incyte Corporation $0.62 04/02/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482175
Principal investigator 1 Incyte Corporation $49.36 04/02/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482182
Principal investigator 1 Incyte Corporation $34.35 04/02/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482187
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482193
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482203
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482208
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Covered Recipient Teaching Hospital
Keck Hospital Of Usc
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240482215
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609871
Principal investigator 1 Incyte Corporation $49.36 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609875
Principal investigator 1 Incyte Corporation $6.18 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609879
Principal investigator 1 Incyte Corporation $10.30 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609881
Principal investigator 1 Incyte Corporation $5.15 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609884
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609886
Principal investigator 1 Incyte Corporation $135.40 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609892
Principal investigator 1 Incyte Corporation $4.24 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609896
Principal investigator 1 Incyte Corporation $22.90 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609899
Principal investigator 1 Incyte Corporation $856.00 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609929
Principal investigator 1 Incyte Corporation $1,609.00 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609934
Principal investigator 1 Incyte Corporation $1,721.00 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609938
Principal investigator 1 Incyte Corporation $3.09 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609989
Principal investigator 1 Incyte Corporation $1,079.00 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610001
Principal investigator 1 Incyte Corporation $1,079.00 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610004
Principal investigator 1 Incyte Corporation $1,079.00 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610009
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610016
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610021
Principal investigator 1 Incyte Corporation $1,721.00 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610029
Principal investigator 1 Incyte Corporation $1,721.00 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610032
Principal investigator 1 Incyte Corporation $1,721.00 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610036
Principal investigator 1 Incyte Corporation $1,721.00 04/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240610041
Principal investigator 1 Incyte Corporation $1,250.00 03/19/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609718
Principal investigator 1 Incyte Corporation $5,000.00 03/19/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609727
Principal investigator 1 Incyte Corporation $5,400.00 03/19/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609731
Principal investigator 1 Incyte Corporation $2,350.00 03/19/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609739
Principal investigator 1 Incyte Corporation $405.00 03/19/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609744
Principal investigator 1 Incyte Corporation $1,500.00 03/19/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609755
Principal investigator 1 Incyte Corporation $1,769.00 03/12/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609723
Principal investigator 1 Incyte Corporation $1,566.00 03/12/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609752
Principal investigator 1 Incyte Corporation $1,625.00 03/12/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609758
Principal investigator 1 Incyte Corporation $1,716.00 03/12/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609767
Principal investigator 1 Incyte Corporation $1,769.00 03/12/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609774
Principal investigator 1 Incyte Corporation $1,625.00 03/12/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609863
Principal investigator 1 Incyte Corporation $8.22 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609640
Principal investigator 1 Incyte Corporation $2.12 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609644
Principal investigator 1 Incyte Corporation $2.12 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609649
Principal investigator 1 Incyte Corporation $270.80 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609657
Principal investigator 1 Incyte Corporation $7.29 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609663
Principal investigator 1 Incyte Corporation $34.35 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609666
Principal investigator 1 Incyte Corporation $22.90 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609673
Principal investigator 1 Incyte Corporation $135.40 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609677
Principal investigator 1 Incyte Corporation $68.70 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609680
Principal investigator 1 Incyte Corporation $16.18 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609684
Principal investigator 1 Incyte Corporation $16.18 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609696
Principal investigator 1 Incyte Corporation $16.18 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609700
Principal investigator 1 Incyte Corporation $57.25 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609783
Principal investigator 1 Incyte Corporation $34.35 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609787
Principal investigator 1 Incyte Corporation $8.22 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609794
Principal investigator 1 Incyte Corporation $8.22 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609798
Principal investigator 1 Incyte Corporation $8.22 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609801
Principal investigator 1 Incyte Corporation $8.22 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609805
Principal investigator 1 Incyte Corporation $8.22 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609808
Principal investigator 1 Incyte Corporation $8.22 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609813
Principal investigator 1 Incyte Corporation $8.22 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609817
Principal investigator 1 Incyte Corporation $135.40 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609833
Principal investigator 1 Incyte Corporation $135.40 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609837
Principal investigator 1 Incyte Corporation $135.40 03/03/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609842
Principal investigator 1 Incyte Corporation $1,757.00 02/10/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609734
Principal investigator 1 Incyte Corporation $1,716.00 02/10/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609748
Principal investigator 1 Incyte Corporation $1,284.30 02/10/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609791
Principal investigator 1 Incyte Corporation $1,716.00 02/10/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609854
Principal investigator 1 Incyte Corporation $1,625.00 01/15/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609688
Principal investigator 1 Incyte Corporation $994.20 01/15/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609691
Principal investigator 1 Incyte Corporation $2,289.00 01/15/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609704
Principal investigator 1 Incyte Corporation $1,625.00 01/15/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609708
Principal investigator 1 Incyte Corporation $1,625.00 01/15/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609713
Principal investigator 1 Incyte Corporation $2,289.00 01/15/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609845
Principal investigator 1 Incyte Corporation $2,289.00 01/15/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609850
Principal investigator 1 Incyte Corporation $1,757.00 01/15/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609859
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,650.00 01/02/2025 Non-covered Recipient Entity
University of Southern California
Speso moderate to severe HS Phase IIb/III No dispute reported 06/30/2026 1220801232
Principal investigator 1 Incyte Corporation $111.30 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609580
Principal investigator 1 Incyte Corporation $90.10 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609584
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609587
Principal investigator 1 Incyte Corporation $84.80 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609592
Principal investigator 1 Incyte Corporation $132.50 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609594
Principal investigator 1 Incyte Corporation $249.10 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609598
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609601
Principal investigator 1 Incyte Corporation $127.20 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609605
Principal investigator 1 Incyte Corporation $74.20 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609607
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609611
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609614
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609617
Principal investigator 1 Incyte Corporation $32.36 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609620
Principal investigator 1 Incyte Corporation $43.04 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609624
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609629
Principal investigator 1 Incyte Corporation $68.70 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609633
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609637
Principal investigator 1 Incyte Corporation $135.40 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609653
Principal investigator 1 Incyte Corporation $180.20 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609763
Principal investigator 1 Incyte Corporation $4.86 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609771
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609778
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609821
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609825
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609829
Principal investigator 1 Incyte Corporation $74.20 01/02/2025 Non-covered Recipient Entity
USC KECK SCHOOL OF MEDICINE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240609866